NCT05009953 - Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

January 16, 2023

Study Completion Date

January 16, 2023

Conditions

Advanced Biliary Tract CancerIntrahepatic CholangiocarcinomaExtrahepatic CholangiocarcinomaGallbladder Carcinoma

Interventions

DRUG

Irinotecan Liposome Injection

Irinotecan Liposome Injection, intravenously, over 90 min on days 1 of every 14-day cycle, 43mg/10mL

DRUG

SG001

Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, intravenously, over 60 min on days 1 of every 14-day cycle, 100mg/10mL

DRUG

Fluorouracil

5-Fluorouracil (5-Fu), intravenously, over 46 h on days 1 of every 14-day cycle

DRUG

Leucovorin

Leucovorin (LV), intravenously, over 30 min on days 1 of every 14-day cycle

Trial Locations (1)

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou